Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen : Genmab Win US FDA Accelerated Approval of Tivdak in Previously Treated Recurrent, Metastatic Cervical Cancer

09/20/2021 | 05:17pm EDT


ę MT Newswires 2021
All news about SEAGEN INC.
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12Seagen Inc. and Astellas Pharma Inc. Complete Enrollment in EV-103 Trial Cohort K Combi..
CI
10/07SEAGEN : to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Re..
BU
10/01WALL STREET STOCK EXCHANGE : Autumn cold snap
10/01ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,..
09/30SEAGEN : JPMorgan Adjusts Seagen PT to $190 From $177, Maintains Overweight Rating
MT
09/28SEAGEN : Completes Patient Enrollment for Phase 2 Trial of Tukysa to Treat Metastatic Colo..
MT
09/28ASTELLAS PHARMA : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelia..
AQ
09/28SEAGEN : Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA« (..
BU
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2021 1 503 M - -
Net income 2021 -419 M - -
Net cash 2021 2 608 M - -
P/E ratio 2021 -74,4x
Yield 2021 -
Capitalization 31 189 M 31 189 M -
EV / Sales 2021 19,0x
EV / Sales 2022 12,9x
Nbr of Employees 2 092
Free-Float 99,3%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 171,43 $
Average target price 186,50 $
Spread / Average Target 8,79%
EPS Revisions
Managers and Directors
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Marc E. Lippman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-2.12%31 189
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
CELLTRION, INC.-38.86%25 455
ALNYLAM PHARMACEUTICALS, INC.52.81%23 604